Prevention and Treatment of Rash in Patients Treated with EGFR Inhibitor Therapies

This is a clinical practice guideline for adult patients with advanced non-small cell lung cancer, colorectal cancer, head/neck cancer, or breast cancer, that is treated with the epidermal growth factor receptor (EGFR) inhibitors cetuximab, erlotinib, gefitinib, panitumumab, or lapatinib, either alone or in combination with other treatments. The guideline examines the prevention and management of a papulopustular rash that commonly develops as a side effect of EGFR inhibitor therapy. Topics of discussion include prevention and prophylactic treatment of rash, clinical management, and supportive care. Outcomes of interest include rash severity, rate of recurrence, and response to treatment.